@Article{info:doi/10.2196/58989,
author="McKee, Hayley
and Eder, Lihi
and Jerome, Dana
and Mirza, D. Reza
and Obetta, Chikaodili
and Pek, Elisabeth
and Piguet, Vincent
and Alhusayen, Raed",
title="Prevalence of Musculoskeletal Symptoms in Patients With Hidradenitis Suppurativa and Associated Factors: Cross-Sectional Study",
journal="JMIR Dermatol",
year="2024",
month="Aug",
day="22",
volume="7",
pages="e58989",
keywords="hidradenitis suppurativa",
keywords="cross sectional",
keywords="skin",
keywords="musculoskeletal symptoms",
keywords="morning stiffness",
keywords="arthralgia",
keywords="comorbidities",
keywords="musculoskeletal",
keywords="comorbidity",
keywords="stiff",
keywords="stiffness",
keywords="muscle",
keywords="muscles",
keywords="muscular",
keywords="prevalence",
keywords="incidence",
keywords="epidemiology",
keywords="epidemiological",
keywords="factor",
keywords="factors",
keywords="dermatology",
keywords="dermatological",
doi="10.2196/58989",
url="https://derma.jmir.org/2024/1/e58989"
}


@Article{info:doi/10.2196/55204,
author="Gawey, Lauren
and Dagenet, B. Caitlyn
and Tran, A. Khiem
and Park, Sarah
and Hsiao, L. Jennifer
and Shi, Vivian",
title="Readability of Information Generated by ChatGPT for Hidradenitis Suppurativa",
journal="JMIR Dermatol",
year="2024",
month="Aug",
day="14",
volume="7",
pages="e55204",
keywords="hidradenitis suppurativa",
keywords="ChatGPT",
keywords="Chat-GPT",
keywords="chatbot",
keywords="chatbots",
keywords="chat-bot",
keywords="chat-bots",
keywords="machine learning",
keywords="ML",
keywords="artificial intelligence",
keywords="AI",
keywords="algorithm",
keywords="algorithms",
keywords="predictive model",
keywords="predictive models",
keywords="predictive analytics",
keywords="predictive system",
keywords="practical model",
keywords="practical models",
keywords="deep learning",
keywords="patient resources",
keywords="readability",
doi="10.2196/55204",
url="https://derma.jmir.org/2024/1/e55204"
}


@Article{info:doi/10.2196/38783,
author="Hardin, Jill
and Murray, Gayle
and Swerdel, Joel",
title="Phenotype Algorithms to Identify Hidradenitis Suppurativa Using Real-World Data: Development and Validation Study",
journal="JMIR Dermatol",
year="2022",
month="Nov",
day="30",
volume="5",
number="4",
pages="e38783",
keywords="dermatology",
keywords="hidradenitis suppurativa",
keywords="medical dermatology",
keywords="observational data",
keywords="phenotype",
keywords="inflammation",
keywords="skin disease",
keywords="epidemiology",
keywords="algorithm",
abstract="Background: Hidradenitis suppurativa (HS) is a potentially debilitating, chronic, recurring inflammatory disease. Observational databases provide opportunities to study the epidemiology of HS. Objective: This study's objective was to develop phenotype algorithms for HS suitable for epidemiological studies based on a network of observational databases. Methods: A data-driven approach was used to develop 4 HS algorithms. A literature search identified prior HS algorithms. Standardized databases from the Observational Medical Outcomes Partnership (n=9) were used to develop 2 incident and 2 prevalent HS phenotype algorithms. Two open-source diagnostic tools, CohortDiagnostics and PheValuator, were used to evaluate and generate phenotype performance metric estimates, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value. Results: We developed 2 prevalent and 2 incident HS algorithms. Validation showed that PPV estimates were highest (mean 86\%) for the prevalent HS algorithm requiring at least two HS diagnosis codes. Sensitivity estimates were highest (mean 58\%) for the prevalent HS algorithm requiring at least one HS code. Conclusions: This study illustrates the evaluation process and provides performance metrics for 2 incident and 2 prevalent HS algorithms across 9 observational databases. The use of a rigorous data-driven approach applied to a large number of databases provides confidence that the HS algorithms can correctly identify HS subjects. ",
doi="10.2196/38783",
url="https://derma.jmir.org/2022/4/e38783",
url="http://www.ncbi.nlm.nih.gov/pubmed/37632892"
}


@Article{info:doi/10.2196/34594,
author="Kulkarni, Vishnutheertha
and Okoye, A. Ginette
and Garza, A. Luis
and Wongvibulsin, Shannon",
title="Geospatial Heterogeneity of Hidradenitis Suppurativa Searches in the United States: Infodemiology Study of Google Search Data",
journal="JMIR Dermatol",
year="2022",
month="Jun",
day="9",
volume="5",
number="2",
pages="e34594",
keywords="hidradenitis suppurativa",
keywords="infodemiology",
keywords="internet",
keywords="digital dermatoepidemiology",
keywords="epidemiology",
keywords="big data",
keywords="dermatology",
doi="10.2196/34594",
url="https://derma.jmir.org/2022/2/e34594",
url="http://www.ncbi.nlm.nih.gov/pubmed/37632873"
}


@Article{info:doi/10.2196/29966,
author="Maghfour, Jalal
and Sivesind, Torunn
and Piguet, Vincent
and Dellavalle, Robert
and Ingram, R. John",
title="From the Cochrane Library: Interventions for Hidradenitis Suppurativa",
journal="JMIR Dermatol",
year="2022",
month="Mar",
day="11",
volume="5",
number="1",
pages="e29966",
keywords="hidradenitis suppurativa",
keywords="quality of life",
keywords="outcome measures",
keywords="heterogenetity in HS research",
keywords="dermatology",
keywords="comorbidities",
keywords="treatment interventions",
keywords="review",
doi="10.2196/29966",
url="https://derma.jmir.org/2022/1/e29966",
url="http://www.ncbi.nlm.nih.gov/pubmed/37632870"
}


@Article{info:doi/10.2196/31047,
author="Finstad, Alexandra
and Lee, Alex
and George, Ralph
and Alhusayen, Raed",
title="Exploring Access to Surgical Interventions for Hidradenitis Suppurativa: Retrospective Population-Based Analysis",
journal="JMIR Dermatol",
year="2021",
month="Dec",
day="14",
volume="4",
number="2",
pages="e31047",
keywords="hidradenitis suppurativa",
keywords="surgery",
keywords="dermatology",
keywords="access",
keywords="epidemiology",
keywords="universal health care",
abstract="Background: Hidradenitis suppurativa (HS) is a painful inflammatory disorder that confers significant distress to patients, with surgery as an integral treatment modality. Objective: To inform improvements in care, patterns in HS surgery were assessed. Methods: A retrospective population-based analysis was performed on Ontario billing claims for HS surgery across a period of 10 years from January 1, 2008 to December 31, 2017. HS surgery was defined as the excision of inguinal, perineal, or axillary skin and sweat glands for hidradenitis. The top 5 billing specialties, including general and plastic surgery, were analyzed. The total number of procedures performed as well as the number performed per physician were investigated. Patient and physician locations were compared. Results: A total of 7195 claims for the excision of inguinal, perineal, or axillary skin and sweat glands for HS were submitted across the study period. Annual HS surgery claims showed an increasing trend across 10 years, ranging between 4.9 and 5.8 per 100,000 population. However, overall, for every additional year, the number of claims per 100,000 population only increased slightly, by 0.03 claims. The number of providers steadily decreased, ranging between 1.7 and 1.9 per 100,000, with approximately twice as many general than plastic surgeons. However, again overall, for every additional year, the number of providers per 100,000 population decreased slightly, by 0.002 physicians. The mean annual number of procedures per physician rose from 2.8 to 3.1. In rural areas, analyzed per claim, general surgeons performed the majority of surgeries (1318/2003, 65.8\%), while in urban areas, surgeries were more equally performed by general (2616/5192, 50.4\%) and plastic (2495/5192, 48.1\%) surgeons. Of HS surgery claims, 25.7\%-35.9\% were provided by a physician residing in a different area than the patient receiving care. Conclusions: No significant improvements in access to HS surgery were seen across the study period, with access potentially worsening with annual HS claims rising overall and number of providers decreasing, with patients travelling further to access surgery. System barriers across the continuum of HS diagnosis and management must be evaluated to improve access to surgical care. ",
doi="10.2196/31047",
url="https://derma.jmir.org/2021/2/e31047",
url="http://www.ncbi.nlm.nih.gov/pubmed/37632848"
}


@Article{info:doi/10.2196/27869,
author="Maghfour, Jalal
and Sivesind, Elise Torunn
and Dellavalle, Paul Robert
and Dunnick, Cory",
title="Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review",
journal="JMIR Dermatol",
year="2021",
month="Oct",
day="1",
volume="4",
number="2",
pages="e27869",
keywords="hidradenitis suppurativa",
keywords="severity of illness index",
keywords="patient-reported outcome measures",
keywords="quality of life",
keywords="treatment outcome",
keywords="illness index",
keywords="patient outcomes",
keywords="disease severity",
keywords="Sartorius",
keywords="dermatology",
keywords="treatment interventions",
abstract="Background: Although there has been an increase in the number of randomized controlled trials evaluating treatment efficacy for hidradenitis suppurativa (HS), instrument measurements of disease severity and quality of life (QoL) are varied, making the compilation of data and comparisons between studies a challenge for clinicians. Objective: We aimed to perform a systematic literature search to examine the recent trends in the use of disease severity and QoL outcome instruments in randomized controlled trials that have been conducted on patients with HS. Methods: A scoping review was conducted in February 2021. The PubMed, Embase, Web of Science, and Cochrane databases were used to identify all articles published from January 1964 to February 2021. In total, 41 articles were included in this systematic review. Results: The HS Clinical Response (HiSCR) score (18/41, 44\%) was the most commonly used instrument for disease severity, followed by the Sartorius and Modified Sartorius scales (combined: 16/41, 39\%). The Dermatology Life Quality Index (18/41, 44\%) and visual analogue pain scales (12/41, 29\%) were the most commonly used QoL outcome instruments in HS research. Conclusions: Randomized controlled trials conducted from 2013 onward commonly used the validated HiSCR score, while older studies were more heterogeneous and less likely to use a validated scale. A few (6/18, 33\%) QoL measures were validated instruments but were not specific to HS; therefore, they may not be representative of all factors that impact patients with HS. Trial Registration: National Institute of Health Research PROSPERO CRD42020209582; https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42020209582 ",
doi="10.2196/27869",
url="https://derma.jmir.org/2021/2/e27869",
url="http://www.ncbi.nlm.nih.gov/pubmed/37632807"
}